Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.52 |
| ▸ | LCK | P06239 | 12/20 | 0.51 |
| ▸ | MET | P08581 | 12/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | TEK | Q02763 | 8/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086395 | 0.96 | KDR (0.52) | KDRLCKMETPDGFRBPDGFRA | |
| SCHEMBL2748078 | 0.92 | PDGFRB (0.60) | KDRLCKMETPDGFRBPDGFRA | |
| SCHEMBL13179130 | 0.84 | KDR (0.54) | KDRLCKMETPDGFRBPDGFRA | |
| SCHEMBL13179261 | 0.84 | KDR (0.54) | KDRLCKMETPDGFRBPDGFRA | |
| SCHEMBL3081654 | 0.83 | KDR (0.55) | KDRLCKMETPDGFRBPDGFRA | |
| SCHEMBL3068055 | 0.83 | KDR (0.55) | KDRLCKMETPDGFRBPDGFRA | |
| SCHEMBL16062321 | 0.74 | PDGFRA (0.59) | KDRMETPDGFRBPDGFRA | |
| SCHEMBL1891385 | 0.73 | PDGFRB (0.64) | KDRPDGFRBPDGFRA | |
| SCHEMBL4233305 | 0.72 | ALDH1A1 (0.49) | AURKA | |
| SCHEMBL31435210 | 0.72 | ALDH1A1 (0.49) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220078-B1 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2220078-B1 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-7795254-B2 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795254-B2 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795254-B2 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2220078-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | Amgen, Inc (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2009058267-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058267-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149454-A1 | Benzomorpholine derivatives and methods of use | BDKRB2, BDKRB1, OPRK1 | KDR 8/4885LCK 2798/4885MET 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.